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Abstract Aims-To examine CD44H and CD44v3 expression in normal gastric and small bowel mucosa, normal and Barrett oesophagus, and oesophageal epithelial malignancies (squamous cell carcinoma and adenocarcinoma). Methods-Ninety five specimens, comprised of 40 of normal oesophageal, gastric and small bowel mucosa, 22 of Barrett oesophagus (two with dysplastic changes), 20 of resected adenocarcinomas, and 13 of squamous cell carcinoma, were evaluated. The samples were fixed in formalin and subsequently stained with anti-CD44H and anti-CD44v3 monoclonal antibodies using the avidin-biotin peroxidase technique.
Results-In contrast to normal oesophagus, which showed positivity for both CD44 epitopes (CD44H and CD44v3) in the basal third of the epithelium, antral and intestinal subtypes of Barrett oesophagus expressed CD44H only, the distribution being focal in non-dysplastic and diffuse in dysplastic Barrett mucosa. Similary, normal antral glands and small bowel epithelium were focally immunopositive for CD44H at the base of the crypts. All squamous cell carcinomas were diffusely positive for both isoforms, whereas 75% (15/20) Differential glycosylation of the extracellular domain of CD44 increases the heterogeneity obtained through alternative splicing. CD44 isoforms modified with glycosaminoglycans such as heparan sulphate contain exon v3. 4 These modified CD44 isoforms behave as proteoglycan-like substances, and have high affinity for some growth factors, such as heparin binding epidermal growth factor (HB-EGF), and could present these growth factors to specific membrane receptors.5 HB-EGF acts as an autocrine growth factor for human keratinocytes. 6 The aim of the present study was to evaluate expression of the CD44H and CD44v3 isoforms in normal and Barrett oesophagus and in the most common oesophageal malignancies, squamous cell carcinoma and adenocarcinoma. The diversity of the CD44H glycoprotein family obtained by means of alternative splicing is further increased by the differential use of numerous N-linked and 0-linked glycosylation sites. Specifically, CD44 isoforms carrying the v3 exon are capable of binding heparan sulphate and can act as proteoglycan-like molecules. These proteoglycan-like CD44 isoforms act as reservoirs for growth factors, and have been implicated in recruitment of growth factors at the cell surface and regulation of their action on target cells. Bennett et al 5 have demonstrated the complexing of HB-EGF and heparan sulphate modified CD44, which suggests a role for CD44 in keratinocyte growth, as HB-EGF is a keratinocyte autocrine growth factor. 6 In the present study CD44H was expressed in the lower third of the squamous epithelium ofnormal oesophageal mucosa and in oesophageal squamous cell carcinoma. A similar pattern of expression was found in gastric and intestinal non-neoplastic and neoplastic mucosa, Barrett oesophagus and adenocarcinoma.
Methods
Expression of CD44v3 has not been found in normal or neoplastic gastric or intestinal mucosa. As in the study by Fox et 
